NICE backs drug for diabetic macular oedema
The National Institute for Health and Clinical Excellence has recommended ranibizumab (Lucentis) for treating visual impairment caused by diabetic macular oedema, after its manufacturer Novartis agreed to provide it at a discounted rate.
Source: Nursing Times Breaking News - Category: Nursing Source Type: news
More News: Diabetes | Endocrinology | Health | Lucentis | National Institute for Health and Clinical Excelle | Nurses | Nursing | Ranibizumab Injection